Devyser Diagnostics AB (Nasdaq: DVYSR) (STO:DVYSR), a provider of genetic test kits for laboratories, on Tuesday declared financial information for its full year from January to December 2022.
The company reported a loss after tax of SEK46.0m, compared to a loss of SEK20.7m in the previous year.
Earnings per share before and after dilution amounted to a loss of SEK2.89 in 2022, versus a loss of SEK1.85 in the year before.
Net sales increased by 35.4% to SEK126.6m, over SEK93.5 in 2021.
Devyser added that its board proposes no dividend for 2022.
AbbVie Inc announces quarterly cash dividend
Qilian International announces special one-time cash dividend
Eli Lilly collaborates with International Agencies (Bangladesh) Ltd
Sanofi reports Q4 sales of Dupixent up 42%
AmeriHealth Caritas Promotes Access to COVID-19 Vaccines for Children Ahead of the Winter Months
Eli Lilly collaborates with EVA Pharma to deliver sustainable supply of affordable insulin to Africa